Summarizing our data, in a study of 11 patients with AGS treated for a median period of 17 months, while we observed a good response of systemic disease features to JAK1/2 inhibition, we saw only limited or no quantifiable benefit on the neurologic manifestations of the disorder. Here, JAK1 is linked to Aicardi-Goutieres syndrome.